Clinical Trial

Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of SLNB in patients with high-risk cSCC and cN0. The primary goal is to evaluate the efficacy of SLNB based on the DFS rate at 2 years post-definitive therapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-16; most recent amendment 2025-07-10.
Status change: Not Yet Recruiting → Recruiting 2025-07-10
Trial Details
NCT Number NCT06990737
Lead Sponsor University of California, Davis
Collaborators: National Cancer Institute (NCI)
Conditions Cutaneous Squamous Cell Carcinoma of the Head and Neck, Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
Enrollment 24 participants
Start Date 2025-06-25
Primary Completion 2031-08-01 (estimated)
Study Completion 2032-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-15